文献速递关节外科

全膝关节置换术中静脉联合关节腔及术后静脉氨甲环酸的安慰剂对照随机试验

Intraoperative Intravenous and Intra-Articular Plus Postoperative Intravenous Tranexamic Acid in Total Knee Arthroplasty: A Placebo-Controlled Randomized Controlled Trial.
PubMed 文献 · J Bone Joint Surg Am · 2020-01-01

这项双盲安慰剂对照随机试验纳入100例初次全膝关节置换术患者,术中均接受静脉联合关节腔氨甲环酸,术后随机接受3次静脉氨甲环酸1000mg或生理盐水。结果显示两组术后第3天围手术期失血量无显著差异,术后静脉氨甲环酸未提供额外减少失血的效果,血栓事件发生率亦无差异。

要点

  • 术中静脉联合关节腔氨甲环酸基础上,术后追加3次静脉氨甲环酸1000mg未进一步减少围手术期失血量。
  • 术后第3天失血量TXA组578±229mL,安慰剂组640±276mL,差异无统计学意义(p=0.23)。
  • 两组术后血栓事件发生率无显著差异(4.3% vs 3.7%,p>0.99)。

核心结论

  • 在术中静脉联合关节腔氨甲环酸的基础上,术后追加静脉氨甲环酸对减少围手术期失血量无额外效果。

研究设计与样本

  • 双盲、安慰剂对照随机对照试验,纳入100例初次全膝关节置换术患者,术中均接受静脉联合关节腔氨甲环酸,按1:1随机分为术后静脉氨甲环酸组(3次1000mg)和安慰剂组(3次生理盐水)。

主要发现

  • 意向性分析显示,术后第3天围手术期失血量TXA组为578±229mL,安慰剂组为640±276mL,差异无统计学意义(95%CI -40至163mL,p=0.23)。
  • 术后血栓事件发生率TXA组4.3%,安慰剂组3.7%,差异无统计学意义(p>0.99)。

关键数值与推荐

  • 主要终点为根据患者血容量和术前至术后第3天血红蛋白差值计算的围手术期失血量。
  • 事后效能分析显示TXA组(n=46)和安慰剂组(n=54)对检测200mL失血量差异的效能>80%。

临床怎么用

  • 对于术中已接受静脉联合关节腔氨甲环酸的全膝关节置换术患者,术后常规追加静脉氨甲环酸可能并无额外减少失血的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combined intraoperative intravenous and intra-articular tranexamic acid (TXA) is 1 of the most effective administration routes to decrease the amount of perioperative blood loss during total knee arthroplasty (TKA). However, the additive effect of postoperative intravenous TXA administration remains unclear. We hypothesized that the postoperative repeated-dose intravenous administration of TXA would provide lower perioperative blood loss. METHODS: We performed a double-blinded, placebo-controlled trial involving patients undergoing primary TKA. A total of 100 patients who were managed with combined intraoperative intravenous and intra-articular TXA were randomly assigned to receive 3 postoperative 1,000-mg doses of intravenous TXA (TXA group) or 3 postoperative doses of intravenous normal saline solution (placebo group) in a 1:1 ratio. The prespecified primary outcome was perioperative blood loss calculated from patient blood volume and the difference in hemoglobin from preoperatively to postoperative day 3. A post hoc power analysis showed that the number of patients allocated to either the TXA group (n = 46) or the placebo group (n = 54) possessed >80% power to detect a 200-mL difference in perioperative blood loss. RESULTS: In the intention-to-treat analysis, we found no significant differences in perioperative blood loss between the TXA group and the placebo group through postoperative day 3 (578 ± 229 compared with 640 ± 276 mL, respectively; 95% confidence interval for the difference, -40 to 163 mL; p = 0.23). The prevalence of postoperative thrombotic events did not differ between the 2 groups (4.3% compared with 3.7%, respectively; p > 0.99). CONCLUSIONS: Postoperative intravenous TXA had no additive effect in reducing perioperative blood loss in patients receiving intraoperative combined intravenous and intra-articular TXA. LEVEL OF EVIDENCE: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Tsukada S, Kurosaka K, Nishino M, et al. Intraoperative Intravenous and Intra-Articular Plus Postoperative Intravenous Tranexamic Acid in Total Knee Arthroplasty: A Placebo-Controlled Randomized Controlled Trial. J Bone Joint Surg Am. 2020. PMID: 32053522. doi:10.2106/JBJS.19.01083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。